Tenaya Therapeutics Announces Closing of Public Offering
21 nov. 2022 17h45 HE
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Announces Pricing of Public Offering
17 nov. 2022 00h39 HE
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Announces Proposed Public Offering
16 nov. 2022 16h01 HE
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
10 nov. 2022 16h05 HE
|
Tenaya Therapeutics, Inc.
Extends Cash Runway to Mid-2024 Commenced Dosing in Phase 1 Clinical Trial of TN-301; Data Expected in 2023 Plans to Submit TN-201 IND by Year End SOUTH SAN FRANCISCO, Calif., Nov. 10, 2022 ...
Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022
04 nov. 2022 08h00 HE
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress
04 oct. 2022 08h30 HE
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions
29 sept. 2022 08h00 HE
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences
29 sept. 2022 07h45 HE
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
06 sept. 2022 16h05 HE
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction
06 sept. 2022 08h00 HE
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially curative...